India's Leading Physicians Cure 49-Year-Old Mauritian Patient

New Delhi: Jason, a 49-year-old businessman from Port Louis, Mauritius, faced a challenging journey through several hospitals in Mauritius due to his severe liver problems.

Jason was diagnosed with Non-Alcoholic Steatohepatitis (NASH) related chronic liver disease, a condition that had silently progressed into a severe form of liver cancer known as Hepatocellular Carcinoma (HCC). The cancer, complicated by portal vein invasion, is particularly aggressive and poses significant treatment challenges.

His persistent health issues led him to Sir Ganga Ram Hospital in New Delhi, where a definitive treatment was made.

HCC, the most common type of primary liver cancer, often results from chronic liver diseases such as hepatitis and cirrhosis. In Jason's case, his condition was a consequence of NASH, a liver disease linked to obesity and metabolic syndrome rather than alcohol consumption. The progression from NASH to HCC can be insidious, often taking years and highlighting the importance of regular medical check-ups for individuals with chronic liver conditions.

The Department of Interventional Radiology at Sir Ganga Ram Hospital, under the leadership of Dr. Arun Gupta, Chairperson of the department, identified Y-90 transarterial radioembolization as the optimal treatment for Jason. This procedure, a promising advancement in the fight against HCC, involves delivering targeted radiation directly to sir ganga ram hospital, dr. arun gupta, non-alcoholic steatohepatitis, nash,liver tumors, thereby minimizing damage to healthy tissues.

"Y-90 transarterial radioembolization represents a significant advancement in the management of hepatocellular carcinoma," Dr. Gupta explained. "By precisely delivering radiation via tiny beads directly into the tumor's blood vessels, we can effectively stop its growth while reducing the impact on the patient's overall health."

During the procedure, radioactive microspheres containing Yttrium-90 (Y-90) are injected into the blood vessels that supply the tumor. These microspheres lodge within the tumor's blood vessels and emit radiation, thereby destroying cancer cells internally. This targeted approach ensures high radiation doses are delivered precisely where needed, sparing healthy liver tissue and minimizing side effects.

Following the procedure, Jason is being closely monitored. Early imaging results have shown promising outcomes, including reduced tumor size and an improved quality of life. This innovative treatment offers renewed hope for patients grappling with this aggressive form of cancer.

Dr. Gupta emphasized the importance of early detection and intervention in managing HCC. "With advancements like Y-90 transarterial radioembolization and improved dosimetry, we are better equipped than ever to combat hepatocellular carcinoma," he noted. As medical innovations continue to evolve, treatments such as Y-90 transarterial radioembolization exemplify the ongoing commitment of healthcare professionals to push boundaries and enhance patient care. For patients like Jason, these advancements not only promise improved outcomes but also a better quality of life, underscoring the relentless pursuit of medical excellence.